StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3019% below fair value
$1.14−0.03 (-2.56%)

Close on Nov 16, 2026Market cap $303.43MP/E –Yield –

Autolus Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Autolus Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 15.7%. For fiscal 2025 it was -27.8%, against -12.5% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-27.8%−15.3
FY2024Dec 31, 2024-12.5%−112.5
FY2023Dec 31, 2023100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q2 FY2026CQ2 2026Jun 30, 202655.2%+72.0
Q1 FY2026CQ1 2026Mar 31, 20266.3%+106.1
Q4 FY2025CQ4 2025Dec 31, 2025-4.3%+39161.2
Q3 FY2025CQ3 2025Sep 30, 2025-35.1%−135.1
Q2 FY2025CQ2 2025Jun 30, 2025-16.8%–
Q1 FY2025CQ1 2025Mar 31, 2025-99.9%–
Q4 FY2024CQ4 2024Dec 31, 2024-39165.5%–
Q1 FY2024CQ1 2024Mar 31, 2024100.0%–

More Autolus Therapeutics figures

See a number that looks wrong?